PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.72%
Revenue growth under 50% of MRVL's 11.65%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
3.20%
Gross profit growth under 50% of MRVL's 10.19%. Michael Burry would be concerned about a severe competitive disadvantage.
-37.64%
Negative EBIT growth while MRVL is at 25.75%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-37.64%
Negative operating income growth while MRVL is at 25.75%. Joel Greenblatt would press for urgent turnaround measures.
-73.68%
Negative net income growth while MRVL stands at 26.89%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-76.92%
Negative EPS growth while MRVL is at 25.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-75.00%
Negative diluted EPS growth while MRVL is at 14.29%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.89%
Share reduction more than 1.5x MRVL's 3.06%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
-0.85%
Reduced diluted shares while MRVL is at 4.10%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-145.79%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
32.57%
Positive FCF growth while MRVL is negative. John Neff would see a strong competitive edge in net cash generation.
265.26%
Similar 10Y revenue/share CAGR to MRVL's 271.49%. Walter Schloss might see both firms benefiting from the same long-term demand.
265.26%
5Y revenue/share CAGR similar to MRVL's 271.49%. Walter Schloss might see both companies benefiting from the same mid-term trends.
100.39%
3Y revenue/share CAGR under 50% of MRVL's 271.49%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-159.80%
Negative 10Y OCF/share CAGR while MRVL stands at 421.95%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-159.80%
Negative 5Y OCF/share CAGR while MRVL is at 421.95%. Joel Greenblatt would question the firm’s operational model or cost structure.
-139.81%
Negative 3Y OCF/share CAGR while MRVL stands at 421.95%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-56.29%
Negative 10Y net income/share CAGR while MRVL is at 315.42%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-56.29%
Negative 5Y net income/share CAGR while MRVL is 315.42%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-81.50%
Negative 3Y CAGR while MRVL is 315.42%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
647.93%
10Y equity/share CAGR at 75-90% of MRVL's 859.66%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
647.93%
5Y equity/share CAGR at 75-90% of MRVL's 859.66%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
128.20%
Below 50% of MRVL's 859.66%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.02%
Firm’s AR is declining while MRVL shows 16.45%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
19.72%
Inventory growth well above MRVL's 27.46%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-18.05%
Negative asset growth while MRVL invests at 4.29%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.49%
Under 50% of MRVL's 1.89%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-97.28%
We’re deleveraging while MRVL stands at 32.31%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
11.33%
R&D growth drastically higher vs. MRVL's 5.54%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
6.28%
SG&A growth well above MRVL's 10.58%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.